TNF and neoplasm: We further demonstrated in mouse model that treatment with B20.4.1.1, the mouse analog of Bevacizumab increased macrophage recruitment to the tumor area and correlated with upregulated TNFα expression in GAMs and increased EC activation, which may be responsible for the failure of AATx in GBMs.